Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
Nasdaq6d
Agios Pharmaceuticals Files for Regulatory Approval of Mitapivat for Thalassemia as Phase 3 RISE UP Study for Sickle Cell Disease Completes Enrollment
Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia ... sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia ...
Sickle Cell disease widespread within tribal population
According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
FOX 5 Atlanta on MSN7d
Cherokee County man cured of sickle cell anemia complications at Atlanta hospital, he says
Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell ...
sicklecellanemianews13d
SCD gene-editing therapy Casgevy now being offered at CHLA
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.